Block listing Interim Review
02 December 2019 15:00 GMT
Block Listing Six Monthly Return
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 2 December 2019
| Name of applicant: | ASTRAZENECA PLC | |||
| Name of scheme: | ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME | |||
| Period of return: | From: | 1 June 2019 | To: | 30 November 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 1,248,036 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 136,370 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1,111,666 | |||
| Name of contact: | CAMILLA JOHNSTONE |
| Telephone number of contact: | 020 3749 5000 |
About AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
| Media Relations | ||
| Gonzalo Viña | +44 203 749 5916 | |
| Rob Skelding | Oncology | +44 203 749 5821 |
| Rebecca Einhorn | Oncology | +1 301 518 4122 |
| Matt Kent | BioPharmaceuticals | +44 203 749 5906 |
| Jennifer Hursit | Other | +44 203 749 5762 |
| Christina Malmberg Hägerstrand | Sweden | +46 8 552 53 106 |
| Michele Meixell | US | +1 302 885 2677 |
| Investor Relations | ||
| Thomas Kudsk Larsen | +44 203 749 5712 | |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Christer Gruvris | BioPharmaceuticals (Cardiovascular, Metabolism) | +44 203 749 5711 |
| Nick Stone | BioPharmaceuticals (Renal) Environmental, Social and Governance | +44 203 749 5716 |
| Josie Afolabi | BioPharmaceuticals (Respiratory) Other medicines | +44 203 749 5631 |
| Craig Marks | Finance Fixed income | +44 7881 615 764 |
| Jennifer Kretzmann | Corporate access Retail investors | +44 203 749 5824 |
| US toll-free | +1 866 381 72 77 |
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.